Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Colon Cancer

12 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCGI15122

01/15/2016

Research Use of Human Biospecimens from Colorectal Cancer Patients (Pilot Study)

Other

VICCGI99003

08/01/2010

Personalized Prevention of Colorectal Cancer

Other

VICCGI0721

01/09/2007

Vanderbilt Hereditary Colorectal Cancer Registry

Prevention

GIS0820-M

07/09/2013

A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

Treatment

VICCGI15126

05/03/2016

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Treatment

VICCMD15110

04/05/2016

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Treatment

VICCGI1623

03/16/2016

A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes with PINPOINT? Near Infrared Fluorescence Imaging in Low Anterior Resection

Treatment

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

VICCPHI1598

12/10/2015

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

Treatment

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

VICCGIP1536

10/26/2015

A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

Treatment

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification